Chemistry: analytical and immunological testing – Process or composition for determination of physical state... – Corrosion resistance or power
Reexamination Certificate
2011-01-18
2011-01-18
Switzer, Juliet C (Department: 1634)
Chemistry: analytical and immunological testing
Process or composition for determination of physical state...
Corrosion resistance or power
C435S091200
Reexamination Certificate
active
07871820
ABSTRACT:
The three β-neurexins have similar roles in synaptogenesis and interact with the neuroligins. Mutations located within the gene encoding neurexin 1 have been identified as molecular markers associated with autism and autism-related disorders. The estimated attributable risk is 2%. The invention provides methods of diagnosing or predicting susceptibility to developing autism in an individual by determining the presence or absence of one or more genetic variant of a neurexin 1 gene in an individual.
REFERENCES:
Philippi et al. Molecular Psychiatry (2005) 10, 950-960.
Sommer et al. (American Journal of Medical Genetics Part B: Neuropsychiatric Genetics; vol. 138B Issue 1, p. 70, (Sep. 5, 2005) Special Issue: XIII World Congress of Psychiatric Genetics 2005; Published Online Sep. 21, 2005).
Print out from American Journal of Medical Genetics Part B website, accessed Apr. 19, 2010. 2 pages.
GeneCard for Neurexin 1 Gene, obtained from http://www.genecards.org/cgi-bin/carddisp.pl?gene=Nrxn1 Apr. 19, 2010, ninteen pages.
Buzin CH, Wen CY, Nguyen VQ, Nozari G, Mengos A, Li X, Chen JS, Liu Q, Gatti RA, Fujimura FK, Sommer SS. 2000. Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic. BioTechniques 28:746-753.
Cook EHJ, Courchesne RY, Cox NJ, Lord C, Gonen D, Guter SJ, Lincoln A, Nix K, Haas R, Leventhal BL, Courchesne E. 1998. Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet 62:1077-1083.
Dean C, Scholl FG, Choih J, DeMaria S, Berger J, Isacoff E, Scheiffele P. 2003. Neurexin mediates the assembly of presynaptic terminals. Nat Neurosci 6:708-716.
Garner CC, Nash J, Huganir RL. 2000. PDZ domains in synapse assembly and signalling. Trends Cell Biol 10:274-280.
Hortsch M, Meyer DI. 1986. Transfer of secretory proteins through the membrane of the endoplasmic reticulum. Int Rev Cytol 102:215-242.
Ichtchenko K, Hata Y, Nguyen T, Ullrich B, Missler M, Moomaw C, Sudhof TC. 1995. Neuroligin 1: a splice site-specific ligand for beta-neurexins. Cell 81:435-443.
Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, Soderstrom H, Giros B, Leboyer M, Gillberg C, Bourgeron T. 2003. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 34:27-29.
Kleiderlein JJ, Nisson PE, Jessee J, Li WB, Becker KG, Derby ML, Ross CA, Margolis RL. 1998. CCG repeats in cDNAs from human brain. Hum Genet 103:666-673.
Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, Hamel BC, Andres C, Barthelemy C, Moraine C, Briault S. 2004. X-linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 74:552-557.
Lobo-Menendez F, Sossey-Alaoui K, Bell JM, Copeland-Yates SA, Plank SM, Sanford SO, Skinner C, Simensen RJ, Schroer RJ, Michaelis RC. 2003. Absence of MeCP2 mutations in patients from the South Carolina autism project. Am J Med Genet B Neuropsychiatr Genet 117:97-101.
Missler M, Sudhof TC. 1998. Neurexins: three genes and 1001 products. Trends Genet 14:20-26.
Rowen L, Young J, Birditt B, Kaur A, Madan A, Philipps DL, Qin S, Minx P, Wilson RK, Hood L, Graveley BR. 2002. Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics 79:587-597.
Schroer RJ, Phelan MC, Michaelis RC, Crawford EC, Skinner SA, Cuccaro M, Simensen RJ, Bishop J, Skinner C, Fender D, Stevenson RE. 1998. Autism and maternally derived aberrations of chromosome 15q. Am J Med Genet 76:327-336.
Tabuchi K, Sudhof TC. 2002. Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. Genomics 79:849-859.
Ullrich B, Ushkaryov YA, Sudhof TC. 1995. Cartography of neurexins: more than 1000 isoforms generated by alternative splicing and expressed in distinct subsets of neurons. Neuron 14:497-507.
Ushkaryov YA, Hata Y, lchtchenko K, Moomaw C, Afendis S, Slaughter CA, Sudhof TC. 1994. Conserved domain structure of beta-neurexins. Unusual cleaved signal sequences in receptor-like neuronal cell-surface proteins. J Biol Chem 269:11987-11992.
von Heijne G. 1986. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res 14:4683-4690.
Yan J, Oliveira G, Coutinho AM, Yang C, Feng J, Katz C, Sram J, Bockholt A, Jones IR, Craddock N, Cook EHJ, Vicente AM, Sommer SS. 2005. Analysis of the neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. Molecular Psychiatry 10:329-332.
Feng Jinong
Sommer Steve S.
Yan Jin
City of Hope
Perkins Coie LLP
Sliger Lauren
Switzer Juliet C
LandOfFree
High frequency of neurexin 1β signal peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High frequency of neurexin 1β signal peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High frequency of neurexin 1β signal peptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2686629